Screener
Indivior Pharmaceuticals, Inc. INDV Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Operating expenses: | ||
| Selling, general and administrative | 124 | 133 |
| Research and development | 16 | 22 |
| Total operating expenses | 139 | 156 |
| Operating income | 137 | 66 |
| Other (income) and expenses: | ||
| Interest (income) | (3) | (4) |
| Interest expense | 7 | 12 |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s other operating expenses?
- Indivior Pharmaceuticals, Inc. (INDV) reported other operating expenses of $139M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s other operating expenses changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s other operating expenses decreased by 10.9% year-over-year, from $156M to $139M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s other operating expenses?
- Over 2 years (2022 to 2024), Indivior Pharmaceuticals, Inc.'s other operating expenses has grown at a 5.5% compound annual growth rate (CAGR), from $827M to $920M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Indivior Pharmaceuticals, Inc.'s other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude